Inchcape Suspends Dividend; To Cut Pays Due To Covid-19 Pandemic

Inchcape Plc (INCH.L), a multi-brand automotive distributor and retailer, announced Tuesday its Board no longer recommends the payment of the previously announced final dividend of 17.9p per ordinary share to preserve cash AMID cOVID-19.

The company further said its Board/ senior management are taking a 20% reduction in fees/ salary during the second quarter to help support the business.

The company said its trading in a large number of markets has been impacted by closures or significantly lower business activity due to coronavirus or Covid-19 crisis.

Meanwhile, 14 markets are still operational, albeit at much reduced levels, including Australia, Ethiopia and Hong Kong. Singapore was operational throughout the first quarter, but a one month lockdown commenced on April 7.

Inchcape has a strong balance sheet, having ended 2019 in a net cash position, aided by strategic retail disposals. The company has liquidity of 600 million pounds as of now.

The company is exploring other debt options to further increase liquidity and flexibility, including the Coronavirus Corporate Financing Facility launched by the UK Government.

The Board on March 20 had put on hold its guidance.

The Company will publish its trading update on May 21.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Salt Lake City, Utah-based Huish Outdoors is recalling Oceanic Adult Dry Top Snorkels sold exclusively at Costco citing risk for drowning, U.S. Consumer Product Safety Commission said. The recall involves about 76,000 units of Oceanic Adult Dry Top Snorkels. The recall was initiated after Oceanic received 13 reports of the snorkels leaking. Boeing expects Europe's commercial aviation fleet to need 8,705 new airplanes through 2040 to cater to the growing leisure travel market in the region and fleet replacements with more fuel-efficient models, according to the Boeing's 2021 Commercial Market Outlook (CMO), an annual forecast of long-term demand for commercial airplanes and services. The U.S. Food and Drug Administration authorized marketing of a software developed by Paige.AI, a provider of AI-based digital diagnostics, which could help pathologists to identify prostate cancer. The software, called Paige Prostate, is the first and only artificial intelligence or AI-based pathology product to receive FDA approval for in vitro diagnostic or IVD use in detecting cancer...
Follow RTT